Compile Data Set for Download or QSAR
Report error Found 66 Enz. Inhib. hit(s) with all data for entry = 1030
TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303815(4-({2-[11-Chloro-7-(fluoromethyl)-2,5-dioxo-5,6,7,...)
Affinity DataIC50: 1.20nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303810(4-{[2-(11′-Chloro-2′,5′-dioxo-2&...)
Affinity DataIC50: 1.80nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303794(4-{[2-(11′-Chloro-2′,5′-dioxo-2&...)
Affinity DataIC50: 1.90nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303807(4-{[2-(11′-Chloro-2′,5′-dioxo-2&...)
Affinity DataIC50: 2.5nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303813(2-[11-Chloro-7-(fluoromethyl)-2,5-dioxo-5,6,7,8-te...)
Affinity DataIC50: 2.80nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303804(5-{[2-(11′-Chloro-2′,5′-dioxo-2&...)
Affinity DataIC50: 4nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303811(2-(11′-Chloro-2′,5′-dioxo-2̸...)
Affinity DataIC50: 4.5nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303812(2-(11′-Chloro-2′,5′-dioxo-2̸...)
Affinity DataIC50: 4.5nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303814(4-({2-[11-Chloro-7-(fluoromethyl)-2,5-dioxo-5,6,7,...)
Affinity DataIC50: 5.30nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303792(4-{[2-(11′-Chloro-2′,5′-dioxo-2&...)
Affinity DataIC50: 7.70nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303797(2-(11′-Chloro-2′,5′-dioxo-2̸...)
Affinity DataIC50: 8.20nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303801(2-(11′-Chloro-2′,5′-dioxo-2̸...)
Affinity DataIC50: 8.40nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303798(2-(11′-Chloro-2′,5′-dioxo-2̸...)
Affinity DataIC50: 11nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303793(2-(11′-Chloro-2′,5′-dioxo-2̸...)
Affinity DataIC50: 16nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303809(2-(11′-Chloro-2′,5′-dioxo-2̸...)
Affinity DataIC50: 18nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303796(2-(11′-Chloro-2′,5′-dioxo-2̸...)
Affinity DataIC50: 18nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303800(2-(11′-Chloro-2′,5′-dioxo-2̸...)
Affinity DataIC50: 21nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303795(4-{[2-(11′-Chloro-2′,5′-dioxo-2&...)
Affinity DataIC50: 27nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303788(4-{[2-(11-Chloro-2,5-dioxo-5,6,7,8-tetrahydropyrid...)
Affinity DataIC50: 28nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303808(4-{[2-(11′-Chloro-2′,5′-dioxo-2&...)
Affinity DataIC50: 34nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303803(5-{[2-(11′-Chloro-2′,5′-dioxo-2&...)
Affinity DataIC50: 34nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303806(4-{[2-(11′-Chloro-2′,5′-dioxo-2&...)
Affinity DataIC50: 35nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303790(4-{[2-(11-Chloro-2,5-dioxo-5,6,7,8-tetrahydropyrid...)
Affinity DataIC50: 36nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303811(2-(11′-Chloro-2′,5′-dioxo-2̸...)
Affinity DataIC50: 42nMAssay Description:o determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the react...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303813(2-[11-Chloro-7-(fluoromethyl)-2,5-dioxo-5,6,7,8-te...)
Affinity DataIC50: 42nMAssay Description:o determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the react...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303789(2-(11-Chloro-2,5-dioxo-5,6,7,8-tetrahydropyrido[3,...)
Affinity DataIC50: 44nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303799(2-(11′-Chloro-2′,5′-dioxo-2̸...)
Affinity DataIC50: 44nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303812(2-(11′-Chloro-2′,5′-dioxo-2̸...)
Affinity DataIC50: 45nMAssay Description:o determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the react...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303802(5-{[2-(11′-Chloro-2′,5′-dioxo-2&...)
Affinity DataIC50: 47nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303810(4-{[2-(11′-Chloro-2′,5′-dioxo-2&...)
Affinity DataIC50: 55nMAssay Description:o determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the react...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303815(4-({2-[11-Chloro-7-(fluoromethyl)-2,5-dioxo-5,6,7,...)
Affinity DataIC50: 97nMAssay Description:o determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the react...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303805(5-{[2-(11′-Chloro-2′,5′-dioxo-2&...)
Affinity DataIC50: 100nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303814(4-({2-[11-Chloro-7-(fluoromethyl)-2,5-dioxo-5,6,7,...)
Affinity DataIC50: 100nMAssay Description:o determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the react...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303791(2-(11-Chloro-2,5-dioxo-5,6,7,8-tetrahydropyrido[3,...)
Affinity DataIC50: 140nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303785(4-{[2-(10′-Chloro-2′,5′-dioxo-5&...)
Affinity DataIC50: 180nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303798(2-(11′-Chloro-2′,5′-dioxo-2̸...)
Affinity DataIC50: 210nMAssay Description:o determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the react...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303796(2-(11′-Chloro-2′,5′-dioxo-2̸...)
Affinity DataIC50: 230nMAssay Description:o determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the react...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303801(2-(11′-Chloro-2′,5′-dioxo-2̸...)
Affinity DataIC50: 230nMAssay Description:o determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the react...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303797(2-(11′-Chloro-2′,5′-dioxo-2̸...)
Affinity DataIC50: 240nMAssay Description:o determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the react...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303809(2-(11′-Chloro-2′,5′-dioxo-2̸...)
Affinity DataIC50: 250nMAssay Description:o determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the react...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303784(2-(10-Chloro-2,5-dioxo-2,5,6,7-tetrahydro-3H-pyrid...)
Affinity DataIC50: 280nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303800(2-(11′-Chloro-2′,5′-dioxo-2̸...)
Affinity DataIC50: 330nMAssay Description:o determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the react...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303804(5-{[2-(11′-Chloro-2′,5′-dioxo-2&...)
Affinity DataIC50: 340nMAssay Description:o determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the react...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303787(2-(11-Chloro-2,5-dioxo-5,6,7,8-tetrahydropyrido[3,...)
Affinity DataIC50: 350nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303807(4-{[2-(11′-Chloro-2′,5′-dioxo-2&...)
Affinity DataIC50: 370nMAssay Description:o determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the react...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303794(4-{[2-(11′-Chloro-2′,5′-dioxo-2&...)
Affinity DataIC50: 390nMAssay Description:o determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the react...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303783(4-{[2-(10-Chloro-2,5-dioxo-2,5,6,7-tetrahydro-3H-p...)
Affinity DataIC50: 420nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303790(4-{[2-(11-Chloro-2,5-dioxo-5,6,7,8-tetrahydropyrid...)
Affinity DataIC50: 680nMAssay Description:o determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the react...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303786(4-{[(11-Chloro-2,5-dioxo-5,6,7,8-tetrahydropyrido[...)
Affinity DataIC50: 720nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM303808(4-{[2-(11′-Chloro-2′,5′-dioxo-2&...)
Affinity DataIC50: 740nMAssay Description:o determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the react...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

Displayed 1 to 50 (of 66 total ) | Next | Last >>
Jump to: